What Is Bimekizumab?
Bimekizumab is an FDA-approved medication for psoriasis. It is a type of drug currently being investigated for its potential to treat various inflammatory conditions. Clinical trials have explored bimekizumab for conditions such as psoriatic arthritis, chronic plaque psoriasis, moderate to severe chronic plaque psoriasis, hidradenitis suppurativa, moderate to severe plaque psoriasis, ankylosing spondylitis, axial spondyloarthritis, and psoriasis vulgaris. The first clinical trial for bimekizumab began on 2015-04-30, and the latest trial is expected to conclude on 2026-03-27. A total of 51 trials have been conducted or are underway, involving 13,863 participants.
Uses and Conditions Under Study
Bimekizumab is being studied for its effects on several inflammatory conditions, primarily those affecting the skin and joints. The majority of research focuses on psoriasis and related conditions.
- Psoriasis and Related Skin Conditions: Bimekizumab has been extensively studied for various forms of psoriasis, including Psoriatic Arthritis (13 trials), Chronic Plaque Psoriasis (11 trials), Moderate to Severe Chronic Plaque Psoriasis (6 trials), Moderate to Severe Plaque Psoriasis (6 trials), Psoriasis (3 trials), and Psoriasis Vulgaris (2 trials). These conditions are characterized by inflammation and skin lesions, and bimekizumab is being investigated for its ability to reduce these symptoms.
- Inflammatory Joint Conditions: The drug is also under investigation for inflammatory conditions that affect the joints and spine. This includes Ankylosing Spondylitis (5 trials) and Axial Spondyloarthritis (3 trials). In these conditions, bimekizumab is being explored for its potential to alleviate pain, stiffness, and inflammation in the spine and other joints.
- Hidradenitis Suppurativa: This chronic inflammatory skin condition, characterized by painful lumps and abscesses, is being studied in 6 trials with bimekizumab. Researchers are evaluating the drug's effectiveness in managing the symptoms and progression of hidradenitis suppurativa.
- Healthy Volunteers: Bimekizumab has also been administered to Healthy Volunteers in 3 trials. These studies are typically conducted to assess the drug's safety, how it is absorbed, distributed, metabolized, and excreted by the body, and to understand its general effects in individuals without the target condition.
Dosing
Bimekizumab is primarily administered as a subcutaneous injection. Clinical trials have investigated specific dosing regimens for the drug.
One studied regimen involves a subcutaneous injection of 320 mg at Weeks 0, 4, 8, 12, and 16, followed by injections every 8 weeks thereafter for 24 weeks. For patients weighing 120 kg or more, a modified regimen of 320 mg every 4 weeks after Week 16 for 24 weeks has been explored.
The brand name Bimzelx is associated with bimekizumab, and the drug has been studied in various forms, including "Bimekizumab 320 mg SC injections." Other trials have explored different bimekizumab dosing regimens, referred to as "Bimekizumab arm 1," "Bimekizumab Dose A," or "Bimekizumab dosing regimen 1," among others, to determine optimal treatment strategies. The specific conditions for which these dosages are intended are typically detailed within the individual trial protocols.
Side Effects
In clinical trials, patients taking Bimekizumab experienced certain side effects more frequently than those on placebo. These findings are based on data from multiple studies involving thousands of patients.
- Nasopharyngitis (common cold symptoms) was reported by 8.2% of patients taking Bimekizumab, compared to 5.0% of patients on placebo.
- Oral candidiasis (thrush) occurred in 5.7% of patients receiving Bimekizumab, while 2.2% of those on placebo experienced it.
- Upper respiratory tract infections were seen in 5.3% of Bimekizumab patients, versus 4.5% of placebo patients.
- Headache affected 4.4% of patients on Bimekizumab, compared to 3.9% on placebo.
- Diarrhea was reported by 4.4% of patients taking Bimekizumab, versus 3.3% on placebo.
- Eczema occurred in 2.8% of patients on Bimekizumab, compared to 1.9% on placebo.
Some other events, such as urinary tract infection, hypertension, and back pain, were reported at similar or lower rates in patients taking Bimekizumab compared to placebo, suggesting they were not directly related to the drug.
Clinical Trial Results
Clinical trials have evaluated the effectiveness of Bimekizumab in treating chronic plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
Chronic Plaque Psoriasis (Study NCT02905006)
In a study of patients with chronic plaque psoriasis, Bimekizumab demonstrated significant improvements compared to placebo after 12 weeks. For the 320 mg dose:
- 93.0% of patients achieved at least a 75% improvement in their Psoriasis Area and Severity Index (PASI) score (PASI75), compared to 4.8% on placebo.
- 79.1% achieved at least a 90% improvement in PASI score (PASI90), while 0% on placebo reached this level.
- 86.
Currently Recruiting Trials
Clinical trials are essential for understanding how new treatments like bimekizumab work and for whom they are most effective. If you are interested in potentially participating in research, several studies are currently recruiting patients to explore different aspects of bimekizumab. One study, NCT07290036, is a Phase 1 trial sponsored by UCB Biopharma SRL. It aims to learn if bimekizumab, when given in different ways, is safe and moves similarly throughout the body over time in adults with Psoriatic Arthritis and Axial Spondyloarthritis. This study plans to enroll 392 participants. Another UCB Biopharma SRL-sponsored study, NCT07219420, is a Phase 3 trial evaluating the efficacy and safety of bimekizumab compared to placebo in 300 participants with Palmoplantar Pustulosis. For mothers receiving treatment with Bimzelx® (bimekizumab), a Phase 1 study (NCT06888193) is assessing the concentration of bimekizumab in mature breast milk. This UCB Biopharma SRL-sponsored trial is recruiting 20 participants with Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, or Hidradenitis Suppurativa. The Centre Hospitalier Universitaire de Nice is sponsoring a Phase 2 study (NCT06742333) with 40 participants to investigate if bimekizumab can delay chronic inflammation in early intervention for Plaque Psoriasis, comparing it to Clobetasol. Additionally, NHS Greater Glasgow and Clyde is conducting a study (NCT06786936) with 50 participants to evaluate the role of IL-17 in depressive symptoms within the context of Psoriatic Arthritis and Psoriatic Plaque. UCB Biopharma SRL is also sponsoring several studies focused on pediatric populations and specific conditions. A Phase 3 study (NCT06921850) is assessing the pharmacokinetics and safety of bimekizumab in 40 children and adolescents with moderate to severe Hidradenitis Suppurativa. Another Phase 3 trial (NCT06668181) is evaluating the pharmacokinetics and safety of bimekizumab in 40 pediatric participants with active Juvenile Idiopathic Arthritis subtypes, including Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis. For those with Moderate to Severe Plaque Psoriasis, with or without Psoriatic Arthritis, a Phase 3 study (NCT06506916) is evaluating the effect of bimekizumab on gene expression biomarkers in 90 participants. Children and adolescents aged 6 to less than 18 years with moderate to severe Plaque Psoriasis can consider a Phase 3 study (NCT06425549) comparing the efficacy and safety of bimekizumab to ustekinumab, aiming for 168 participants. Finally, the Icahn School of Medicine at Mount Sinai is sponsoring a Phase 4 study (NCT06336343) with 60 participants to evaluate bimekizumab's effectiveness and safety in individuals with moderate-to-severe Plaque Psoriasis who have not responded to similar therapies.Where to Participate
Clinical trials for bimekizumab are currently recruiting across a wide geographic area, offering opportunities for participation in various locations. These studies span 54 sites across 47 cities and 20 states. Some of the top recruiting locations include:- Miami, Florida (2 sites)
- South Miami, Florida (2 sites)
- Whittier, California (2 sites)
- New York, New York (2 sites)
- Santa Monica, California (2 sites)
- Fountain Valley, California (2 sites)
- Arlington, Texas (2 sites)
Development Timeline
The development journey for bimekizumab began on April 30, 2015, with its first clinical trial. Since then, a total of 51 trials have been initiated, enrolling over 13,863 participants, with the latest trial expected to conclude by March 27, 2026. UCB Biopharma SRL has been the primary driving force behind bimekizumab's development, sponsoring 36 of these trials. Initial investigations explored conditions such as IBS-C and hyperphosphatemia. Over time, the research pipeline significantly expanded, focusing on a broader range of immune-mediated inflammatory diseases. This expansion included studies for Moderate to Severe Chronic Plaque Psoriasis, Hidradenitis Suppurativa, Ankylosing Spondylitis, and Axial Spondyloarthritis. As development progressed, bimekizumab was also studied for Active Psoriatic Arthritis, Rheumatoid Arthritis, Atopic Dermatitis, and various forms of Psoriasis, including Psoriasis Vulgaris and Palmoplantar Pustulosis. More recently, trials have explored its potential in pediatric conditions like Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis, and even in related areas such as depression in the context of immune-mediated inflammatory diseases. The majority of trials have advanced to later stages, with 24 Phase 3 studies and 14 Phase 2 studies completed or ongoing, indicating a robust and comprehensive evaluation of bimekizumab's potential.